Jennifer Dziwanowski, NP
Nurse Practitioner · New Bern, NCNPI 1386629988
Payments from drug & device makers
Across 130 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$243
- AbbVie$189
- Grifols USA, LLC$183
- Johnson & Johnson$175
- GSK$116
- Actelion Pharmaceuticals US, Inc.$116
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,173100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $243 |
| AbbVie | 9 | $189 |
| Grifols USA, LLC | 10 | $183 |
| Johnson & Johnson(2 entities) | 12 | $175 |
| GSK | 7 | $116 |
| Actelion Pharmaceuticals US, Inc. | 7 | $116 |
| Novo Nordisk | 6 | $109 |
| Lundbeck LLC | 4 | $90 |
| AstraZeneca(2 entities) | 4 | $74 |
| Amarin Pharma, Inc. | 5 | $68 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Lilly USA, LLC | 3 | $56 |
| CSL Behring | 3 | $52 |
| Pfizer | 3 | $42 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Corcept Therapeutics | 3 | $36 |
| Organon | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Novartis | 2 | $34 |
| Boehringer Ingelheim | 1 | $33 |
| Medtronic | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Amgen | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Corium, LLC | 1 | $24 |
| Merck | 1 | $22 |
| UCB, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Argenx US, Inc. | 1 | $14 |
| United Therapeutics Corporation | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,173 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $92,474 |
| JardianceEmpagliflozin | 119 | $88,407 |
| TrulicityDulaglutide | 49 | $57,595 |
| RybelsusSemaglutide | 20 | $30,065 |
| XareltoRivaroxaban | 39 | $29,464 |
| EliquisApixaban | 30 | $29,240 |
| MounjaroTirzepatide | 21 | $21,900 |
| MyrbetriqMirabegron | 30 | $15,480 |
| FarxigaDapagliflozin Propanediol | 17 | $13,908 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $12,724 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 50 | $11,146 |
| LinzessLinaclotide | 19 | $10,423 |
| Atorvastatin Calcium | 387 | $4,008 |
| Omeprazole | 332 | $3,318 |
| Dexlansoprazole DrDexlansoprazole | 18 | $3,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $109 | $122,53993 claims |
| Boehringer IngelheimJardiance | $33 | $88,407119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $56 | $79,49570 claims |
| Johnson & JohnsonXarelto | $175 | $29,46439 claims |
| PfizerEliquis | $42 | $29,24030 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $15,48030 claims |
| AstraZenecaFarxiga | $74 | $13,90817 claims |
| GSKShingrix | $116 | $11,14650 claims |
| AbbVieLinzess | $189 | $10,42319 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $1,933356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in New Bern
- Vinetta McCannNew Bern$16K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.